Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20395893 | 0.87 | MAPT (0.44) | ADRB2LMNARAB9AADRB1ADRB3 | |
| SCHEMBL4871580 | 0.86 | PLA2G2A (0.42) | BCHEACHECYP2D6ADRB2KCNH2 | |
| Hydrogen Sulfide SCHEMBL20395882 | 0.86 | MAPT (0.43) | ADRB2LMNARAB9AADRB1ADRB3 | |
| SCHEMBL644117 | 0.84 | MAPT (0.44) | ADRB2LMNARAB9AADRB1ADRB3 | |
| SCHEMBL2533186 | 0.84 | ADRB2 (0.39) | ADRB2LMNARAB9AADRB1ADRB3 | |
| SCHEMBL644523 | 0.83 | CA1 (0.43) | ADRB2RAB9AADRB1ADRB3BLM | |
| SCHEMBL4873232 | 0.81 | ADRB2 (0.40) | ADRB2LMNARAB9AADRB1ADRB3 | |
| SCHEMBL3550177 | 0.80 | RAB9A (0.48) | BCHEACHECYP2D6ADRB2KCNH2 | |
| SCHEMBL2530033 | 0.80 | ATM (0.41) | ADRB2LMNARAB9AADRB1ADRB3 | |
| SCHEMBL4878299 | 0.79 | KAT6A (0.51) | ADRB2LMNARAB9AADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | BCHE 44/4885ACHE 130/4885CYP2D6 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.